BiVictriX Therapeutics (BVX) Share Price, News & Analysis

Company Overview

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 10 to 10
• 52-Week Range: N/A
• Volume: 1.54 million shs
• Average Volume: 108,326 shs
• Market Capitalization: £8.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVX Stock Analysis - Frequently Asked Questions

How do I buy shares of BiVictriX Therapeutics?

Shares of BVX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of BiVictriX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiVictriX Therapeutics investors own include AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX), Abacus Health Products (ABAHF) and Aurora Cannabis (ACB).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:BVX
• CUSIP: N/A
• CIK: N/A
• Web: www.bivictrix.com
• Phone: N/A
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-2,670,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -103.99%
• Return on Assets: -62.99%

Debt

• Debt-to-Equity Ratio: 8.81
• Current Ratio: 4.40
• Quick Ratio: 7.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 2.20
• Book Value: GBX 3 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 82,530,000
• Free Float: N/A
• Market Cap: £8.25 million
• Optionable: Not Optionable
• Beta: -0.73